No abstract available.
Fees and Charges* ; Insurance*

No abstract available.
Esophageal Neoplasms*

No abstract available.

BACKGROUND: We evaluated 1) the sequential changes of angiotensin-converting enzyme (ACE) mRNA expression in lung (main site for circulating ACE synthesis) and left ventricle, and 2) whether such expression is modified by ACE inhibitor or angiotensin II receptor blocker treatment after acute myocardial infarction (MI) in rats. METHODS: Placebo, captopril (2 g/liter drinking water) or TCV-116 (10 mg/kg/day gavage) was administered 3 days before left coronary occlusion and continued for 6 weeks. At 1, 3 and 6 weeks after operation, hemodynamic measurement was performed and pulmonary and myocardial ACE mRNA expression was analyzed by quantitative RT-PCR using rcRNA as an internal standard. RESULTS: Mean BP and LVEDP increased in untreated rats compared with captopril- and TCV-116-treated rats (post-MI 6week, p<0.05). Pulmonary ACE mRNA increased in acute phase (post-MI 1 week, max. 1.4 fold, p<0.05 vs. pre-MI) and returned to pre-MI value thereafter. In contrast, cardiac ACE mRNA expression showed slightly decreasing tendency in acute phase, and was increased up to 1.6 fold in chronic phase after MI (post-MI 3 and 6weeks, p<0.05 vs. pre-MI). No changes in pulmonary ACE gene expression were found with RAS blockade. However, in acute phase after MI, cardiac ACE mRNA increased with both captopril and TCV-116 treatment (post-MI 24hour and 1week, max. 2 fold, p<0.05 vs. untreated group). CONCLUSION: 1) In contrast to the pulmonary ACE mRNA that is activated in acute phase, the cardiac ACE mRNA is activated in chronic phase after MI. 2) RAS blockade does not affect the change of pulmonary ACE expression, but modulate the change of cardiac ACE expression after MI.
Animals ; Captopril ; Coronary Occlusion ; Drinking ; Gene Expression* ; Heart Ventricles ; Hemodynamics ; Lung* ; Myocardial Infarction* ; Myocardium* ; Peptidyl-Dipeptidase A ; Rats ; Receptors, Angiotensin ; RNA, Messenger

No abstract available.
Heart Valves* ; Heart*

No abstract available.
Korea* ; Thoracic Surgery*

No abstract available.

No abstract available.
Paragonimiasis*

No abstract available.
Asthma

Churg-Strauss syndrome is a rare systemic necrotizing vasculitis that is characterized by asthma, peripheral eosinophilia, non-fixed pulmonary infiltrates, neuropathy and histopathologic features of extravascular eosinophilic infiltration and granuloma formation. Churg-Strauss syndrome is accompanied by asthma in nearly all cases. However, a few atypical cases of Churg-Strauss syndrome without asthma or eosinophilia have been reported. An 18-year-old male was referred for discoloration of right second finger, and right foot drop. He developed peripheral eosinophilia, bilateral pulmonary infiltrates, mononeuritis multiplex, extravascular eosinophilic infiltration on lung biopsy, and vasculitis on medium to small sized arteries of upper and lower extremities without asthma. We report an atypical case of an 18-year-old male patient diagnosed as Churg-Strauss syndrome without preexisting asthma.
Adolescent ; Arteries ; Asthma ; Biopsy ; Churg-Strauss Syndrome ; Eosinophilia ; Eosinophils ; Fingers ; Foot ; Granuloma ; Humans ; Lower Extremity ; Lung ; Male ; Mononeuropathies ; Vasculitis